Clinical Trial: NCT04414163
A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 2| Lead Sponsor: | ImmuneOncia Therapeutics Inc. |
| Information Provided By: | ImmuneOncia Therapeutics Inc. |
| Last Update Posted: | 2026-09-24 |
Study Overview
Brief Summary
This is a phase 2, Open-label, to investigate the efficacy and safety of IMC-001 in patients with Relapsed or Refractory extranodal NK/T cell lymphoma, nasal type
Official Title
An Open-label, Single-arm, Phase 2 Study to Investigate the Efficacy and Safety of IMC-001 in Patients With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type
Conditions
Extranodal NK/T-cell Lymphoma, Nasal Type, Extranodal NK/T-cell Lymphoma
Intervention / Treatment
- Drug: IMC-001
Other Study ID Numbers
- IMC-001-201
Start Date (Actual)
2020-10-27
Primary Completion Date (Actual)
2024-07-23
Study Completion Date (Estimated)
2027-02-28
Enrollment (Actual)
23
Study Type
Interventional
Phase
Phase 2
| Lead Sponsor: | ImmuneOncia Therapeutics Inc. |
| Information Provided By: | ImmuneOncia Therapeutics Inc. |
| Last Update Posted: | 2026-09-24 |
Study Overview
Brief Summary
This is a phase 2, Open-label, to investigate the efficacy and safety of IMC-001 in patients with Relapsed or Refractory extranodal NK/T cell lymphoma, nasal type
Official Title
An Open-label, Single-arm, Phase 2 Study to Investigate the Efficacy and Safety of IMC-001 in Patients With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type
Conditions
Extranodal NK/T-cell Lymphoma, Nasal Type, Extranodal NK/T-cell Lymphoma
Intervention / Treatment
- Drug: IMC-001
Other Study ID Numbers
- IMC-001-201
Start Date (Actual)
2020-10-27
Primary Completion Date (Actual)
2024-07-23
Study Completion Date (Estimated)
2027-02-28
Enrollment (Actual)
23
Study Type
Interventional
Phase
Phase 2